Invasive lobular carcinoma (ILC) is the second most common type of breast cancer and accounts for 10-15% of the 280,000 annual cases in the United States. ILC is an understudied breast cancer, and currently there are no specific treatment strategies designed for this unique breast cancer subtype, despite high long-term risk of recurrence. The Lobular Breast Cancer Research Program is committed to addressing the critical gap in ILC diagnostic and treatment strategies.